Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
27
2
2021
medline:
28
4
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
The aim of this study was to explore weight gain in people with HIV (PWH) at least 65 years of age who switch to a DTG based regimen (DTG-s) vs. remaining INSTI-naive (INSTI-n) on stable ART. This was a longitudinal prospective study of PWH from the GEPPO cohort. At the beginning of the observational period, participants were INSTI-naives (INSTI-n). During follow-up, they were divided in two groups: INSTI-n vs. dolutegravir-switchers (DTG-s) with no further change in ART. Body weight was assessed at baseline and at last follow-up visit. Significant weight gain was defined as an increase at least 5% of baseline weight from the first to the last visit. ART regimens were collected at each patients' visit. Kaplan--Meier curves were drawn to assess time to reach a weight gain more than 5%. Out of 568 PWH (83.1% men, median age 69.5 years), 427 (75%) were INSTI-n and 141 (25%) DTG-s. After an average follow-up of 2.6 (±0.8) years, no significant change in body weight was observed both among INSTI-n [delta weight = 0.02 (±7.5), P = 0.633] and DTG-s [delta weight = -0.04 (±5.2), P = 0.755]. Weight gain was also not significantly different between study groups (9.3% in INSTI-n and 15.1% in DTG-S: P = 0.175). No significant differences in time to achieve a weight gain greater or equal than 5% of baseline weight emerged in INSTI-n vs. DTG-s (P = 0.93), two-drug regimens (2DR) vs. three-drug regimens (3DR) (P = 0.56) or TAF vs. TDF (P = 0.56). Results from a large Italian cohort did not show a significant weight gain associated with switch to DTG in PWH 65 years of age or older. This finding emerged also when comparing 3DR vs. 2DR and TAF exposed and unexposed geriatric PWH.
Identifiants
pubmed: 33635844
doi: 10.1097/QAD.0000000000002853
pii: 00002030-202105010-00010
pmc: PMC9904432
doi:
Substances chimiques
HIV Integrase Inhibitors
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
939-945Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity . JAMA 2003; 289:187–193.
Tam BT, Morais JA, Santosa S. Obesity and ageing: two sides of the same coin . Obes Rev 2020; 21:e12991.
Quach A, Levine ME, Tanaka T, Lu AT, Chen BH, Ferrucci L, et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors . Aging (Albany NY) 2017; 9:419–446.
Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection . Clin Infect Dis 2017; 64:1422–1429.
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population . Clin Infect Dis 2011; 53:1120–1126.
Erlandson KM, Taejaroenkul S, Smeaton L, Gupta A, Singini IL, Lama JR, et al. A randomized comparison of anthropomorphic changes with preferred and alternative efavirenz-based antiretroviral regimens in diverse multinational settings . Open Forum Infect Dis 2015; 2:ofv095.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV . N Engl J Med 2019; 381:803–815.
Burns JE, Stirrup OT, Dunn D, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV . AIDS 2020; 34:109–114.
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations . Nat Rev Dis Primers 2020; 6:48.
Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, et al. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study . J Antimicrob Chemother 2017; 72:2879–2886.
Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, et al. Role of normalized T-cell subsets in predicting comorbidities in a large cohort of geriatric HIV-infected patients . J Acquir Immune Defic Syndr 2017; 76:338–342.
Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, et al. The increasing burden and complexity of multimorbidity and polypharmacy in geriatric HIV patients: a cross sectional . BMC Geriatr 2018; 18:1–10.
Guidelines EACS 2018. http//www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html [Assessed 21 July 2019]. 2018; (October):1–19.
Focà E, Fabbiani M, Prosperi M, Quiros Roldan E, Castelli F, Maggiolo F, et al. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study . Medicine (Baltimore) 2016; 95:e4091.
Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens . J Acquir Immune Defic Syndr United States 2017; 76:527–531.
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk factors for weight gain following switch to integrase inhibitor–based antiretroviral therapy. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa177 .
Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, et al. A Phase 3b, multicenter, open-label study switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide(E/C/F/TAF) or a Tenofovir disoproxil fumarate containing regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in virolo. IOS, Mex City, Mex 2019. http//programme.ias2019.org/Abstract/Abstract/1453 . [Accessed 20 June 2020].
Verboeket S. Switching to an integrase inhibitor containing antiretroviral regimen is not associated with above-average weight gain in middle-aged people living with HIV on long-term suppressive antiretroviral therapy, the AGEhIV cohort study. EACS 2019. http://europeanaidsconference.eacs.cyim.com/mediatheque/media.aspx?mediaId=78045&channel=28172/ [Accessed 20 June 2020].
Seidell JC, Visscher TL. Body weight and weight change and their health implications for the elderly . Eur J Clin Nutr 2000; 54: (Suppl 3): S33–S39.
Dey DK, Rothenberg E, Sundh V, Bosaeus I, Steen B. Body mass index, weight change and mortality in the elderly. A 15 y longitudinal population study of 70 y olds . Eur J Clin Nutr 2001; 55:482–492.